KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Common Equity (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Common Equity for 9 consecutive years, with -$119.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 74.96% year-over-year to -$119.2 million, compared with a TTM value of -$119.2 million through Dec 2025, up 74.96%, and an annual FY2025 reading of -$119.2 million, up 74.96% over the prior year.
  • Common Equity was -$119.2 million for Q4 2025 at Biocryst Pharmaceuticals, up from -$387.9 million in the prior quarter.
  • Across five years, Common Equity topped out at -$119.2 million in Q4 2025 and bottomed at -$476.2 million in Q1 2024.
  • Average Common Equity over 3 years is -$405.0 million, with a median of -$436.8 million recorded in 2025.
  • The sharpest move saw Common Equity tumbled 45.05% in 2024, then soared 74.96% in 2025.
  • Year by year, Common Equity stood at -$455.5 million in 2023, then fell by 4.48% to -$475.9 million in 2024, then skyrocketed by 74.96% to -$119.2 million in 2025.
  • Business Quant data shows Common Equity for BCRX at -$119.2 million in Q4 2025, -$387.9 million in Q3 2025, and -$421.6 million in Q2 2025.